The rotenone model of parkinsonism--the five years inspection.

Treatment of rats with rotenone has been proposed in the year 2000 to provide an animal model of idiopathic Parkinson's disease. We review here the experience that has been gained meanwhile with this model. The published data suggest that the model does not ideally reproduce the pathophysiology of Parkinson's disease, that Rotenone treatment does not cause a purely neurodegenerative concondition, that the Rotenone model does not ideally recapitulate the motor symptoms of Parkinson's disease, that degeneration of the dopaminergic neurons is highly variable, that striatal neurons appear to degenerate more consistently than neurons in the substantia nigra, and that cytoplasmic accumulation of the tau protein is more abundant than alpha-synuclein aggregation in severely lesioned animals. In summary, these data suggest that Rotenone-treated rats model atypical Parkinsonism rather than idiopathic Parkinson's disease.

[1]  Nicolas Lapointe,et al.  Rotenone induces non‐specific central nervous system and systemic toxicity , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  James M. Krueger,et al.  Sleep disturbances in the rotenone animal model of Parkinson disease , 2005, Brain Research.

[3]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[4]  C. Marsden,et al.  Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease , 1990, Journal of neurochemistry.

[5]  A. Schapira,et al.  Metabolic enzyme expression in dopaminergic neurons in Parkinson's disease: An in situ hybridization study , 2001, Annals of neurology.

[6]  Jean Féger,et al.  The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy , 2005, Journal of neurochemistry.

[7]  Todd B. Sherer,et al.  Subcutaneous Rotenone Exposure Causes Highly Selective Dopaminergic Degeneration and α-Synuclein Aggregation , 2003, Experimental Neurology.

[8]  Jean Féger,et al.  Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats , 2003, Journal of neurochemistry.

[9]  Cheryl D. DiCarlo,et al.  Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone , 2004, Experimental Neurology.

[10]  M. Chesselet,et al.  Variable effects of chronic subcutaneous administration of rotenone on striatal histology , 2004, The Journal of comparative neurology.

[11]  J. Schulz,et al.  Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra , 1997, Brain Research.